-

Bristol-Myers Squibb Postpones April 2, 2020 Investor Day

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that due to the ongoing COVID-19 pandemic, it will reschedule its planned April 2, 2020 Investor Day for a later date. The company will continue to assess the situation and follow guidance from local and global health authorities to determine the new date.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

Contacts

Bristol-Myers Squibb
Media:
media@bms.com
609-252-3345

Investors:
Tim Power, 609-252-7509, timothy.power@bms.com
Nina Goworek, 908-673-9711, ngoworek@bms.com

Industry:

Bristol-Myers Squibb Company

NYSE:BMY
Release Summary
Bristol-Myers Squibb Postpones April 2, 2020 Investor Day
Release Versions
English
$Cashtags
$BMY

Contacts

Bristol-Myers Squibb
Media:
media@bms.com
609-252-3345

Investors:
Tim Power, 609-252-7509, timothy.power@bms.com
Nina Goworek, 908-673-9711, ngoworek@bms.com

More News From Bristol-Myers Squibb Company

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study

BOTHELL, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)--Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung......

Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients......

Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study

BOTHELL, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)--Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2-......
Back to Newsroom